Gene Medicine Research Group, NDCLS, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Respiratory Infections, National Heart and Lung Institute, Imperial College London, London, UK.
Sci Rep. 2021 Aug 3;11(1):15694. doi: 10.1038/s41598-021-95150-z.
Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
呼吸道合胞病毒（RSV）感染是婴儿和老年人住院的常见原因。帕利珠单抗预防是唯一批准的治疗方式，但价格昂贵，只提供给选定的弱势群体。在这里，我们通过重组腺相关病毒（rAAV2/8）和猴免疫缺陷病毒（rSIV.F/HN）载体研究了基因传递方法，以在小鼠模型中实现帕利珠单抗的持续体内产生。在 RSV 攻击前 28 天递送表达帕利珠单抗的载体可完全防止 RSV 引起的体重减轻。这种方法提供了针对 RSV 感染的预防措施，允许在弱势群体中更广泛地使用和降低治疗成本。
